Exhibit 10.67
SECURITIES PURCHASE
AGREEMENT
This Securities Purchase Agreement
(this “ Agreement ”) is dated as of
January 29, 2009, between AVI BioPharma, Inc., an Oregon
corporation (the “ Company ”), and each
purchaser identified on the signature pages hereto (each,
including its successors and assigns, a “ Purchaser
” and collectively the “ Purchasers
”).
WHEREAS, subject to the terms and
conditions set forth in this Agreement and pursuant to an effective
registration statement under the Securities Act of 1933, as amended
(the “ Securities Act ”), the Company desires to
issue and sell to each Purchaser, and each Purchaser, severally and
not jointly, desires to purchase from the Company, securities of
the Company as more fully described in this Agreement.
NOW, THEREFORE, IN CONSIDERATION of
the mutual covenants contained in this Agreement, and for other
good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as
follows:
ARTICLE I.
DEFINITIONS
1.1
Definitions
. In addition to the terms
defined elsewhere in this Agreement, for all purposes of this
Agreement, the following terms have the meanings set forth in this
Section 1.1:
“ Acquiring Person
” shall have the meaning ascribed to such term in
Section 4.5.
“ Action ” shall
have the meaning ascribed to such term in
Section 3.1(j).
“ Affiliate ”
means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under
Rule 405 under the Securities Act.
“ Board of Directors
” means the board of directors of the Company.
“ Business Day ”
means any day except any Saturday, any Sunday, any day which is a
federal legal holiday in the United States or any day on which
banking institutions in the State of New York are authorized or
required by law or other governmental action to close.
“ Closing ” means
the closing of the purchase and sale of the Securities pursuant to
Section 2.1.
“ Closing Date ”
means the Trading Day on which all of the Transaction Documents
have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchasers’
obligations to pay the Subscription Amount and (ii) the
Company’s obligations to deliver the Securities, in each
case, have been satisfied or waived, which is expected to be
January 30, 2009, but in any event in accordance with
Rule 15c6-1 promulgated under the Exchange Act.
1
“ Closing Price ”
means on any particular date (a) the last reported closing bid
price per share of Common Stock on such date on the Trading Market
(as reported by Bloomberg L.P. at 4:15 p.m. (New York City
time)), (b) if there is no such price on such date, then the
closing bid price on the Trading Market on the date nearest
preceding such date (as reported by Bloomberg L.P. at
4:15 p.m. (New York City time)), (c) if the Common Stock
is not then listed or quoted on a Trading Market and if prices for
the Common Stock are then reported in the “pink sheets”
published by Pink OTC Markets, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the
most recent bid price per share of the Common Stock so reported, or
(d) if the shares of Common Stock are not then publicly traded
the fair market value as of such date of a share of Common Stock as
determined by an independent appraiser selected in good faith by
the Purchasers of a majority in interest of the Shares then
outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.
“ Closing Statement
” means the Closing Statement in the form on Annex A
attached hereto.
“ Commission
” means the United States Securities and Exchange
Commission.
“ Common Stock ”
means the common stock of the Company, par value $0.0001 per share,
and any other class of securities into which such securities may
hereafter be reclassified or changed.
“ Common Stock
Equivalents ” means any securities of the Company or the
Subsidiaries which would entitle the holder thereof to acquire at
any time Common Stock, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, Common
Stock.
“ Company Counsel
” means Davis Wright Tremaine LLP, Attn: Michael C Phillips,
with offices located at 23 rd Floor, 1300 SW Fifth Ave., Portland,
Oregon 97201.
“ Disclosure Schedules
” means the Disclosure Schedules of the Company delivered
concurrently herewith.
“ Evaluation Date
” shall have the meaning ascribed to such term in
Section 3.1(r).
“ Exchange Act ”
means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder.
“ Exempt Issuance
” means the issuance of (a) shares of Common Stock or
options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a
majority of the non-employee members of the Board of Directors or a
majority of the members of a committee of non-employee directors
established for such purpose, (b) securities upon the exercise
or exchange of or conversion of any Securities issued hereunder
and/or other securities exercisable or exchangeable for or
convertible into shares of Common Stock issued and outstanding
on
2
the date of this Agreement, provided
that such securities have not been amended since the date of this
Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such
securities, and (c) securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the
disinterested directors of the Company, provided that any such
issuance shall only be to a Person (or to the equityholders of a
Person) which is, itself or through its subsidiaries, an operating
company or an asset in a business synergistic with the business of
the Company and shall provide to the Company additional benefits in
addition to the investment of funds, but shall not include a
transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary
business is investing in securities.
“ FDA ” shall
have the meaning ascribed to such term in
Section 3.1(gg).
“ FDCA ” shall
have the meaning ascribed to such term in
Section 3.1(gg).
“ FWS ”
means Feldman Weinstein & Smith LLP with offices located
at 420 Lexington Avenue, Suite 2620, New York, New York
10170-0002.
“ GAAP ” shall
have the meaning ascribed to such term in
Section 3.1(h).
“ Indebtedness ”
shall have the meaning ascribed to such term in
Section 3.1(z).
“ Intellectual Property
Rights ” shall have the meaning ascribed to such term in
Section 3.1(o).
“ Liens ” means a
lien, charge, security interest, encumbrance, right of first
refusal, preemptive right or other restriction.
“ Material Adverse
Effect ” shall have the meaning assigned to such term in
Section 3.1(b).
“ Material Permits
” shall have the meaning ascribed to such term in
Section 3.1(m).
“ Per Share Purchase
Price ” equals $1.16, subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and
other similar transactions of the Common Stock that occur after the
date of this Agreement.
“ Person ” means
an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“ Pharmaceutical
Product ” shall have the meaning ascribed to such term in
Section 3.1(gg).
3
“ Proceeding ”
means an action, claim, suit, investigation or proceeding
(including, without limitation, an informal investigation or
partial proceeding, such as a deposition), whether commenced or
threatened.
“ Prospectus ”
means the final prospectus filed for the Registration
Statement.
“ Prospectus Supplement
” means the supplement to the Prospectus complying with
Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the
Closing.
“ Purchaser Party
” shall have the meaning ascribed to such term in
Section 4.8.
“ Registration
Statement ” means the effective registration statement
with Commission file No. 333-138299 which registers the sale
of the Shares, the Warrants and the Warrant Shares by the
Purchasers.
“ Required Approvals
” shall have the meaning ascribed to such term in
Section 3.1(e).
“ Rule 144 ”
means Rule 144 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the
Commission having substantially the same effect as such
Rule.
“ Rule 424 ”
means Rule 424 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter
adopted by the Commission having substantially the same purpose and
effect as such Rule.
“ SEC Reports
” shall have the meaning ascribed to such term in
Section 3.1(h).
“ Securities ”
means the Shares, the Warrants and the Warrant Shares.
“ Securities Act
” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.
“ Shares ” means
the shares of Common Stock issued or issuable to each Purchaser
pursuant to this Agreement.
“ Short Sales ”
means all “short sales” as defined in Rule 200 of
Regulation SHO under the Exchange Act (but shall not be deemed to
include the location and/or reservation of borrowable shares of
Common Stock).
“ Subscription
Amount ” means, as to each Purchaser, the aggregate
amount to be paid for Shares and Warrants purchased hereunder as
specified below such Purchaser’s name on the signature
page of this Agreement and next to the heading
“Subscription Amount,” in United States dollars and in
immediately available funds.
4
“ Subsidiary ”
means any subsidiary of the Company as set forth on Schedule
3.1(a) , and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the
date hereof.
“ Trading Day ”
means a day on which the principal Trading Market is open for
trading.
“ Trading Market
” means any of the following markets or exchanges on which
the Common Stock is listed or quoted for trading on the date in
question: the NYSE Alternext, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange or the OTC Bulletin Board (or any successors to any of the
foregoing).
“ Transaction Documents
” means this Agreement, the Warrants and any other documents
or agreements executed in connection with the transactions
contemplated hereunder.
“ Transfer Agent
” means BNY Mellon Shareowner Services, the current transfer
agent of the Company, with a mailing address of 480 Washington
Boulevard, Jersey City, NJ 07310 and a facsimile number of
201-680-4620, and any successor transfer agent of the
Company.
“ Variable Rate
Transaction ” shall have the meaning ascribed to such
term in Section 4.12(b).
“ Warrants ”
means, collectively, the Common Stock purchase warrants delivered
to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, which Warrants shall be
exercisable six months after the issue date and have a term of
exercise equal to five years, in the form of Exhibit A
attached hereto.
“ Warrant Shares
” means the shares of Common Stock issuable upon exercise of
the Warrants.
ARTICLE II.
PURCHASE AND SALE
2.1
Closing . On the Closing Date, upon the terms and
subject to the conditions set forth herein, substantially
concurrent with the execution and delivery of this Agreement by the
parties hereto, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, up to an
aggregate of $16,500,077 of Shares and Warrants. Each
Purchaser shall deliver to the Company, via wire transfer or a
certified check of immediately available funds equal to such
Purchaser’s Subscription Amount as set forth on the signature
page hereto executed by such Purchaser and the Company shall
deliver to each Purchaser its respective Shares and a Warrant as
determined pursuant to Section 2.2(a), and the Company and each
Purchaser shall deliver the other items set forth in Section 2.2
deliverable at the Closing. Upon satisfaction of the
covenants and conditions set forth in Sections 2.2 and 2.3, the
Closing shall occur at the offices of FWS or such other location as
the parties shall mutually agree.
5
2.2
Deliveries
.
(a)
On or prior to the Closing Date, the Company shall deliver or cause
to be delivered to each Purchaser the following:
(i)
this Agreement
duly executed by the Company;
(ii)
a legal opinion
of Company Counsel, substantially in the form of
Exhibit B attached hereto;
(iii)
a copy of the
irrevocable instructions to the Company’s transfer agent
instructing the transfer agent to deliver via the Depository Trust
Company Deposit Withdrawal Agent Commission System (“
DWAC ”) Shares equal to such Purchaser’s
Subscription Amount divided by the Per Share Purchase Price,
registered in the name of such Purchaser;
(iv)
a Warrant
registered in the name of such Purchaser to purchase up to a number
of shares of Common Stock equal to 100% of the number of Shares
purchased by such Purchaser, with an exercise price equal to $1.16,
subject to adjustment therein (such Warrant certificate may be
delivered within three Trading Days of the Closing Date);
and
(v)
the Prospectus
and Prospectus Supplement (which may be delivered in accordance
with Rule 172 under the Securities Act).
(b)
On or prior to
the Closing Date, each Purchaser shall deliver or cause to be
delivered to the Company the following:
(i)
this Agreement
duly executed by such Purchaser; and
(ii)
such
Purchaser’s Subscription Amount by wire transfer to the
account as specified in writing by the Company.
2.3
Closing Conditions
.
(a)
The obligations of the Company hereunder in connection with the
Closing are subject to the following conditions being
met:
(i)
the accuracy in
all material respects on the Closing Date of the representations
and warranties of the Purchasers contained herein (unless as of a
specific date therein);
(ii)
all obligations,
covenants and agreements of each Purchaser required to be performed
at or prior to the Closing Date shall have been performed;
and
(iii)
the delivery by
each Purchaser of the items set forth in
Section 2.2(b) of this Agreement.
6
(b)
The respective
obligations of the Purchasers hereunder in connection with the
Closing are subject to the following conditions being
met:
(i)
the accuracy in
all material respects when made and on the Closing Date of the
representations and warranties of the Company contained herein
(unless as of a specific date therein);
(ii)
all obligations,
covenants and agreements of the Company required to be performed at
or prior to the Closing Date shall have been performed;
(iii)
the delivery by
the Company of the items set forth in Section 2.2(a) of
this Agreement;
(iv)
there shall have
been no Material Adverse Effect with respect to the Company since
the date hereof; and
(v)
from the date
hereof to the Closing Date, trading in the Common Stock shall not
have been suspended by the Commission or the Company’s
principal Trading Market (except for any suspension of trading of
limited duration agreed to by the Company, which suspension shall
be terminated prior to the Closing), and, at any time prior to the
Closing Date, trading in securities generally as reported by
Bloomberg L.P. shall not have been suspended or limited, or minimum
prices shall not have been established on securities whose trades
are reported by such service, or on any Trading Market, nor shall a
banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any
material outbreak or escalation of hostilities or other national or
international calamity of such magnitude in its effect on, or any
material adverse change in, any financial market which, in each
case, in the reasonable judgment of each Purchaser, makes it
impracticable or inadvisable to purchase the Securities at the
Closing.
ARTICLE III.
REPRESENTATIONS AND WARRANTIES
3.1
Representations and Warranties of
the Company .
Except as set forth in the Disclosure Schedules, which Disclosure
Schedules shall be deemed a part hereof and shall qualify any
representation or otherwise made herein to the extent of the
disclosure contained in the corresponding section of the Disclosure
Schedules, the Company hereby makes the following representations
and warranties to each Purchaser:
(a)
Subsidiaries
. All of the direct and
indirect subsidiaries of the Company are set forth on Schedule
3.1(a). The Company owns, directly or indirectly, all of the
capital stock or other equity interests of each Subsidiary free and
clear of any Liens, and all of the issued and outstanding shares of
capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities. If the Company has no
subsidiaries, all other references to the Subsidiaries or any of
them in the Transaction Documents shall be disregarded.
7
(b)
Organization and Qualification . The Company and each
of the Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and, to the extent applicable under the
laws of the respective state of incorporation, in good
standing under the laws of the jurisdiction of its incorporation or
organization, with the requisite power and authority to own and use
its properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other
organizational or charter documents. Each of the Company and
the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each
jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the
case may be, could not have or reasonably be expected to result in:
(i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material
adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and
the Subsidiaries, taken as a whole, or (iii) a material
adverse effect on the Company’s ability to perform in any
material respect on a timely basis its obligations under any
Transaction Document (any of (i), (ii) or (iii), a “
Material Adverse Effect ”) and no Proceeding has been
instituted in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and
authority or qualification.
(c)
Authorization; Enforcement . The Company has the
requisite corporate power and authority to enter into and to
consummate the transactions contemplated by each of the Transaction
Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of each of the
Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and
no further action is required by the Company, the Board of
Directors or the Company’s stockholders in connection
therewith other than in connection with the Required
Approvals. Each Transaction Document to which it is a party
has been (or upon delivery will have been) duly executed by the
Company and, when delivered in accordance with the terms hereof and
thereof, will constitute the valid and binding obligation of the
Company enforceable against the Company in accordance with its
terms, except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by
applicable law.
(d)
No Conflicts . The execution, delivery and performance
by the Company of the Transaction Documents, the issuance and sale
of the Securities and the consummation by it of the transactions
contemplated hereby and thereby to which it is a party do not and
will not (i) conflict with or violate any provision of the
Company’s or any Subsidiary’s certificate or articles
of incorporation, bylaws or other organizational or charter
documents, or (ii) conflict with, or constitute a default (or
an event that with notice or lapse of time or both would become a
default) under, result in the creation of
8
any Lien upon any
of the properties or assets of the Company or any Subsidiary, or
give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of,
any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or
by which any property or asset of the Company or any Subsidiary is
bound or affected, or (iii) subject to the Required Approvals,
conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the
Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the
case of each of clauses (ii) and (iii), such as could not have
or reasonably be expected to result in a Material Adverse
Effect.
(e)
Filings, Consents and Approvals . The Company is not
required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any
court or other federal, state, local or other governmental
authority or other Person in connection with the execution,
delivery and performance by the Company of the Transaction
Documents, other than: (i) the filings required pursuant to
Section 4.4 of this Agreement, (ii) the filing with the
Commission of the Prospectus Supplement,
(iii) application(s) to each applicable Trading Market
for the listing of the Securities for trading thereon in the time
and manner required thereby and (iv) such filings as are
required to be made under applicable state securities laws
(collectively, the “ Required Approvals
”).
(f)
Issuance of the Securities; Registration . The
Securities are duly authorized and, when issued and paid for in
accordance with the applicable Transaction Documents, will be duly
and validly issued, fully paid and nonassessable, free and clear of
all Liens imposed by the Company. The Warrant Shares, when
issued in accordance with the terms of the Warrants, will be
validly issued, fully paid and nonassessable, free and clear of all
Liens imposed by the Company. The Company has reserved from
its duly authorized capital stock the maximum number of shares of
Common Stock issuable pursuant to this Agreement and the Warrants.
The Company has prepared and filed the Registration Statement in
conformity with the requirements of the Securities Act, which
became effective on November 22, 2006 (the “
Effective Date ”), including the Prospectus, and such
amendments and supplements thereto as may have been required to the
date of this Agreement. The Registration Statement is
effective under the Securities Act and no stop order preventing or
suspending the effectiveness of the Registration Statement or
suspending or preventing the use of the Prospectus has been issued
by the Commission and no proceedings for that purpose have been
instituted or, to the knowledge of the Company, are threatened by
the Commission. The Company, if required by the
rules and regulations of the Commission, proposes to file the
Prospectus, with the Commission pursuant to Rule 424(b).
At the time the Registration Statement and any amendments
thereto became effective, at the date of this Agreement and at the
Closing Date, the Registration Statement and any amendments thereto
conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any
material fact required
9
to be stated
therein or necessary to make the statements therein not misleading;
and the Prospectus and any amendments or supplements thereto, at
time the Prospectus or any amendment or supplement thereto was
issued and at the Closing Date, conformed and will conform in all
material respects to the requirements of the Securities Act and did
not and will not contain an untrue statement of a material fact or
omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they
were made, not misleading. The offering and sale of the Securities
(the “ Offering ”) are being made pursuant the
Registration Statement (including the Prospectus contained therein
(the “ Base Prospectus ”)) filed by the Company
with the Securities and Exchange Commission (the
“Commission”), (2) if applicable, certain
“free writing prospectuses” (as that term is defined in
Rule 405 under the Securities Act), that have been or will be
filed with the Commission and delivered to the Purchasers on or
prior to the date hereof, and (3) a Prospectus Supplement (the
“ Prospectus Supplement ” and together with the
Base Prospectus, the “Prospectus”) containing certain
supplemental information regarding the Securities and terms of the
Offering that have been or will be filed with the Commission and
has been or will be delivered to the Purchasers (or made available
to the Purchasers by the filing by the Company of an electronic
version thereof with the Commission on or prior to the time the
Purchasers have executed this Agreement, other than the Prospectus
Supplement which shall be filed with the Commission no later than
two (2) days subsequent to the execution of this
Agreement).
(g)
Capitalization . The capitalization of the Company is
as set forth on Schedule 3.1(g) . The Company has not
issued any capital stock since its most recently filed periodic
report under the Exchange Act, other than pursuant to the exercise
of employee stock options under the Company’s stock option
plans, the issuance of shares of Common Stock to employees pursuant
to the Company’s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of
first refusal, preemptive right, right of participation, or any
similar right to participate in the transactions contemplated by
the Transaction Documents. Except as a result of the purchase
and sale of the Securities and except as set forth on Schedule
3.1(g) , there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations
convertible into or exercisable or exchangeable for, or giving any
Person any right to subscribe for or acquire, any shares of Common
Stock, or contracts, commitments, understandings or arrangements by
which the Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or Common Stock
Equivalents. The issuance and sale of the Securities will not
obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Purchasers) and will not
result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange or reset price under any of such
securities. All of the outstanding shares of capital stock of the
Company are validly issued, fully paid and nonassessable, have been
issued in compliance with all federal and state securities laws,
and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase
securities. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the
issuance and sale of the Securities. There are no
stockholders agreements, voting agreements or other
10
similar
agreements with respect to the Company’s capital stock to
which the Company is a party or, to the knowledge of the Company,
between or among any of the Company’s
stockholders.
(h)
SEC Reports; Financial Statements . The Company has
filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and
the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, for the two years preceding the date hereof (or
such shorter period as the Company was required by law or
regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by
reference therein, together with the Prospectus and the Prospectus
Supplement, being collectively referred to herein as the “
SEC Reports ”) on a timely basis or has received a
valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of
their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Reports, when
filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The
Company has never been an issuer subject to
Rule 144(i) under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all
material respects with applicable accounting requirements and the
rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis during
the periods involved (“ GAAP ”), except as may
be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not
contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its
consolidated Subsidiaries as of and for the dates thereof and the
results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.
(i)
Material Changes; Undisclosed Events, Liabilities or
Developments . Since the date of the latest audited
financial statements included within the SEC Reports, except as
specifically disclosed in a subsequent SEC Report filed prior to
the date hereof, (i) there has been no event, occurrence or
development that has had or that could reasonably be expected to
result in a Material Adverse Effect, (ii) the Company has not
incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the
ordinary course of business consistent with past practice and
(B) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or disclosed
in filings made with the Commission, (iii) the Company has not
altered its method of accounting, (iv) the Company has not
declared or made any dividend or distribution of cash or other
property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock
and (v) the Company has not issued any equity securities to
any officer, director or Affiliate, except pursuant to existing
Company stock option plans. Except for the
issuance of the Securities contemplated by this Agreement or as set
forth on Schedule 3.1(i) , no event, liability, fact,
circumstance, occurrence or development has occurred or
11
exists or is
reasonably expected to occur or exist with respect to the Company
or its Subsidiaries or their respective business, prospects,
properties, operations, assets or financial condition that would be
required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that
has not been publicly disclosed at least 1 Trading Day prior to the
date that this representation is made.
(j)
Litigation . There is no action, suit, inquiry, notice
of violation, proceeding or investigation pending or, to the
knowledge of the Company, threatened against or affecting the
Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative
agency or regulatory authority (federal, state, county, local or
foreign) (collectively, an “ Action ”) which
(i) adversely affects or challenges the legality, validity or
enforceability of any of the Transaction Documents or the
Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material
Adverse Effect. Neither the Company nor any Subsidiary, nor
any director or officer thereof, is or has been the subject of any
Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the
Company, there is not pending or contemplated, any investigation by
the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not
issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or any
Subsidiary under the Exchange Act or the Securities
Act.
(k)
Labor Relations . No material labor dispute exists or,
to the knowledge of the Company, is imminent with respect to any of
the employees of the Company, which could reasonably be expected to
result in a Material Adverse Effect. None of the
Company’s or its Subsidiaries’ employees is a member of
a union that relates to such employee’s relationship with the
Company or such Subsidiary, and neither the Company nor any of its
Subsidiaries is a party to a collective bargaining agreement, and
the Company and its Subsidiaries believe that their relationships
with their employees are good. No executive officer, to the
knowledge of the Company, is, or is now expected to be, in
violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or
non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and, to the
knowledge of the Company, the continued employment of each
such executive officer does not subject the Company or any of its
Subsidiaries to any liability with respect to any of the foregoing
matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms
and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
(l)
Compliance . Neither the Company nor any Subsidiary:
(i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of
time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received
notice of a claim that
12
it is in default
under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a
party or by which it or any of its properties is bound (whether or
not such default or violation has been waived), (ii) is in
violation of any judgment, decree or order of any court, arbitrator
or governmental body or (iii) is or has been in violation of
any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state
and local laws applicable to its business and all such laws that
affect the environment, except in each case as could not have or
reasonably be expected to result in a Material Adverse Effect or as
otherwise disclosed in the Company’s SEC
Reports..
(m)
Regulatory Permits . The Company and the Subsidiaries
possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities
necessary to conduct their respective businesses as described in
the SEC Reports, except where the failure to possess such permits
could not reasonably be expected to result in a Material Adverse
Effect (“ Material Permits ”), and neither the
Company nor any Subsidiary has received any notice of proceedings
relating to the revocation or modification of any Material
Permit.
(n)
Title to Assets . The Company and the Subsidiaries
have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal
property owned by them that is material to the business of the
Company and the Subsidiaries, in each case free and clear of all
Liens, except for Liens as do not materially affect the value of
such property and do not materially interfere with the use made and
proposed to be made of such property by the Company and the
Subsidiaries and Liens for the payment of federal, state or other
taxes, the payment of which is neither delinquent nor subject to
penalties. Any real property and facilities held under lease
by the Company and the Subsidiaries are held by them under valid,
subsisting and enforceable leases with which the Company and the
Subsidiaries are in compliance.
(o)
Patents and Trademarks . The Company and the
Subsidiaries have, or have rights to use, all patents, patent
applications, trademarks, trademark applications, service marks,
trade names, trade secrets, inventions, copyrights, licenses and
other intellectual property rights and similar rights necessary or
material for use in connection with their respective businesses as
described in the SEC Reports and which the failure to so have could
have a Material Adverse Effect (collectively, the “
Intellectual Property Rights ”). Neither the
Company nor any Subsidiary has received a notice (written or
otherwise) that any of the Intellectual Property Rights used by the
Company or any Subsidiary violates or infringes upon the rights of
any Person. To the knowledge of the Company, all such
Intellectual Property Rights are enforceable and there is no
existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken
reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
13
(p)
Insurance . The Company and the Subsidiaries are
insured against such losses and risks and in such amounts as are
prudent and customary in the businesses in which the Company and
the Subsidiaries are engaged, including, but not limited to,
directors and officers insurance coverage. Neither the
Company nor any Subsidiary has any reason to believe that it will
not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a
significant increase in cost.
(q)
Transactions With Affiliates and Employees . Except as
set forth in the SEC Reports, none of the officers or directors of
the Company and, to the knowledge of the Company, none of the
employees of the Company is presently a party to any “related
party transaction, as defined in the Rules and Regulations,
with the Company or any Subsidiary (other than for services as
employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from
any
|